Browse studies

Find your next paid study

5 recruiting studies matching your filters

A Multicenter, Open-label Study of QRX003 Lotion in Participants With Netherton Syndrome

This is a multicenter, open-label study to evaluate the safety, tolerability, and efficacy of 4% QRX003 lotion applied twice daily (BID) for 12 weeks to Nether…

Netherton Syndrome

Estimated

~$10 – $8,750

Quoin PharmaceuticalsNCT07538583

Phase 2

A Multicenter, Open Label Study of QRX003 Lotion in Subjects With Netherton Syndrome

To assess the safety, tolerability, and efficacy of QRX003 lotion (4%) when added to standard of care treatment regimen, including systemic therapy in subjects…

Netherton Syndrome

Estimated

~$10 – $8,750

Quoin PharmaceuticalsNCT05789056

Phase 2

A Single Center, Open Label, Expanded Access Study of QRX003 Lotion in Subjects With Netherton Syndrome

The goal of this clinical trial (via an expanded access Treatment Protocol) is to learn if QRX003 (an investigational drug) applied topically to the skin (incl…

Netherton Syndrome

Estimated

~$10 – $8,750

Quoin PharmaceuticalsNCT06953466

Phase 1

A Phase 1/1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Ascending Doses of BCX17725 in Healthy Participants and Multiple Doses of BCX17725 in Participants With Netherton Syndrome

This is a first-in-human, Phase 1/1b, 4-part study that includes the evaluation of safety, tolerability, pharmacokinetics (PK), and immunogenicity of BCX17725 …

Netherton Syndrome

Estimated

~$10 – $8,750

BioCryst PharmaceuticalsNCT06539507

Phase 1

A Randomized, Double-Blind, Vehicle-Controlled, First-in-Human Safety, Tolerability and Proof-of-Concept Study of Topical ATR12-351 in Adults With Netherton Syndrome

The objectives of this clinical trial are to evaluate the safety and tolerability of topically applied ATR12-351, to understand what the body does to ATR12-351…

Netherton Syndrome

Estimated

~$10 – $8,750

Azitra Inc.NCT06137157